Innate Pharma's Preclinical Success with IPH45: A Nectin-4 Targeted ADC Unveiled at AACR 2024

Innate Pharma SA has disclosed the initial findings from preclinical research on IPH45, an innovative exatecan-linked Antibody Drug Conjugate (ADC) with a focus on Nectin-4. This data reveal was part of a spoken address at the 2024 American Association for Cancer Research (AACR) Annual Meeting.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

During early-stage scientific assessments, evidence has shown that the compound IPH45 successfully blocks the growth of Nectin-4 positive cancer cells in both lab dish settings and live animal experiments. This includes models not responding to Enfortumab Vedotin. Notably, IPH45 outperforms EV in a range of patient-derived xenograft (PDX) models for urothelial cancer, functioning effectively in contexts with both high and low Nectin-4 expression. Moreover, when combined with anti-PD1 therapy in animal studies, IPH45 enhances the suppression of tumor progression, while maintaining an acceptable tolerability profile in toxicological evaluations conducted on animals.

”IPH45 represents a distinct and innovative Nectin-4 targeting Antibody Drug Conjugate, showcasing promising effectiveness in preclinical tumor models with different Nectin-4 expression profiles. Its utilization of the exatecan payload presents heightened effectiveness for impacting surrounding cells and extends the treatment window when compared to ADCs conjugated with MMAE,” noted Prof. Eric Vivier, DVM, PhD, the Chief Scientific Officer at Innate Pharma.

He further emphasized the compound's capability to shape future treatments for patients diagnosed with various Nectin-4 reliant cancers, even extending beyond those with elevated Nectin-4 like bladder cancer. Given these positive outcomes, the thrust to propel IPH45 into clinical development phases is strong.

Nectin-4, which is an adhesive protein located on cell surfaces, is typically overexpressed in an array of solid malignancies such as those affecting the urothelial, breast, lung, ovarian, and pancreas tissues, with minimal presence in normal healthy tissues. IPH45, a new exatecan-conjugated Antibody Drug Conjugate, zeroes in on Nectin-4. Lasting well in animal models, IPH45 reveals its potential to attack tumors both outside and inside the body’s living systems. Currently, IPH45 is advancing toward its initial trial involving human participants.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

According to the data provided by the Synapse Database, As of April 11, 2024, there are 42 investigational drugs for the Nectin-4 target, including 28 indications, 46 R&D institutions involved, with related clinical trials reaching 77, and as many as 2348 patents.

IPH-45 is an antibody drug conjugate and fusion protein that targets nectin-4, a protein associated with neoplasms. It is being developed by Innate Pharma SA for the treatment of neoplasms. Currently in the preclinical phase, IPH-45 is undergoing testing to determine its safety and efficacy before progressing to clinical trials.